inclusion criteria: 1. signed written informed consent from any patient capable of giving consent, or, when the patient is incapable of doing so, by his or her legal/authorized representative. note: in accordance with the european medicines agency (ema) "guidance on the management of clinical trials during the covid-19 (coronavirus) pandemic version 3 28/04/2020", if written consent by the trial participant is not possible (for example because of physical isolation due to covid-19 infection), consent may be given orally by the trial participant in the presence of an impartial witness. 2. age 18 years or older. 3. patient is currently hospitalized. 4. diagnosis of covid-19 pneumonia including a positive rt-pcr test for sars-cov-2 of any specimen and lung involvement confirmed with chest imaging (x-ray or computed tomography \[ct\] scan). 5. able to comply with the study protocol. 6. female patients must be postmenopausal (24 months of amenorrhea), surgically sterile or must agree to use an effective method of contraception throughout the study and for up to 120 days after stopping treatment. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.

inclusion criteria: 1. signed written informed consent from any patient capable of giving consent, or, when the patient is incapable of doing so, by his or her legal/authorized representative. note: in accordance with the european medicines agency (ema) "guidance on the management of clinical trials during the covid-19 (coronavirus) pandemic version 3 28/04/2020", if written consent by the trial participant is not possible (for example because of physical isolation due to covid-19 infection), consent may be given orally by the trial participant in the presence of an impartial witness. 2. age 18 years or older. 3. patient is currently hospitalized. 4. diagnosis of covid-19 pneumonia including a positive rt-pcr test for sars-cov-2 of any specimen and lung involvement confirmed with chest imaging (x-ray or computed tomography \[ct\] scan). 5. able to comply with the study protocol. 6. female patients must be postmenopausal (24 months of amenorrhea), surgically sterile or must agree to use an effective method of contraception throughout the study and for up to 120 days after stopping treatment. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.

inclusion criteria: signed written informed consent from any patient capable of giving consent, or, when the patient is incapable of doing so, by his or her legal/authorized representative. note: in accordance with the european medicines agency (ema) "guidance on the management of clinical trials during the covid-19 (coronavirus) pandemic version 3 28/04/2020", if written consent by the trial participant is not possible (for example because of physical isolation due to covid-19 infection), consent may be given orally by the trial participant in the presence of an impartial witness. age 18 years or older. patient is currently hospitalized. diagnosis of covid-19 pneumonia including a positive rt-pcr test for sars-cov-2 of any specimen and lung involvement confirmed with chest imaging (x-ray or computed tomography [ct] scan). able to comply with the study protocol. female patients must be postmenopausal (24 months of amenorrhea), surgically sterile or must agree to use an effective method of contraception throughout the study and for up to 120 days after stopping treatment. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.

inclusion criteria: signed written informed consent from any patient capable of giving consent, or, when the patient is incapable of doing so, by his or her legal/authorized representative. note: in accordance with the european medicines agency (ema) "guidance on the management of clinical trials during the covid-19 (coronavirus) pandemic version 3 28/04/2020", if written consent by the trial participant is not possible (for example because of physical isolation due to covid-19 infection), consent may be given orally by the trial participant in the presence of an impartial witness. age 18 years or older. patient is currently hospitalized. diagnosis of covid-19 pneumonia including a positive rt-pcr test for sars-cov-2 of any specimen and lung involvement confirmed with chest imaging (x-ray or computed tomography [ct] scan). able to comply with the study protocol. female patients must be postmenopausal (24 months of amenorrhea), surgically sterile or must agree to use an effective method of contraception throughout the study and for up to 120 days after stopping treatment. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.

inclusion criteria: 1. signed written informed consent from any patient capable of giving consent, or, when the patient is incapable of doing so, by his or her legal/authorized representative. note: in accordance with the european medicines agency (ema) "guidance on the management of clinical trials during the covid-19 (coronavirus) pandemic version 3 28/04/2020", if written consent by the trial participant is not possible (for example because of physical isolation due to covid-19 infection), consent may be given orally by the trial participant in the presence of an impartial witness. 2. age 18 years or older. 3. patient is currently hospitalized. 4. diagnosis of covid-19 pneumonia including a positive rt-pcr test for sars-cov-2 of any specimen and lung involvement confirmed with chest imaging (x-ray or computed tomography [ct] scan). 5. able to comply with the study protocol. 6. female patients must be postmenopausal (24 months of amenorrhea), surgically sterile or must agree to use an effective method of contraception throughout the study and for up to 120 days after stopping treatment. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.

inclusion criteria: 1. signed written informed consent from any patient capable of giving consent, or, when the patient is incapable of doing so, by his or her legal/authorized representative. note: in accordance with the european medicines agency (ema) "guidance on the management of clinical trials during the covid-19 (coronavirus) pandemic version 3 28/04/2020", if written consent by the trial participant is not possible (for example because of physical isolation due to covid-19 infection), consent may be given orally by the trial participant in the presence of an impartial witness. 2. age 18 years or older. 3. patient is currently hospitalized. 4. diagnosis of covid-19 pneumonia including a positive rt-pcr test for sars-cov-2 of any specimen and lung involvement confirmed with chest imaging (x-ray or computed tomography [ct] scan). 5. able to comply with the study protocol. 6. female patients must be postmenopausal (24 months of amenorrhea), surgically sterile or must agree to use an effective method of contraception throughout the study and for up to 120 days after stopping treatment. effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.